Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials  Edward.

Similar presentations


Presentation on theme: "Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials  Edward."— Presentation transcript:

1 Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials  Edward V. Loftus, Jean-Frederic Colombel, Stefan Schreiber, Charles W. Randall, Miguel Regueiro, Tauseef Ali, Catherine Arendt, Jason Coarse, Marshall Spearman, Gordana Kosutic  Clinical Gastroenterology and Hepatology  Volume 14, Issue 12, Pages (December 2016) DOI: /j.cgh Copyright © 2016 AGA Institute Terms and Conditions

2 Figure 1 Incidence rates of AEs, serious AEs, infections, and serious infections (new cases per 100 patient-years). Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions


Download ppt "Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials  Edward."

Similar presentations


Ads by Google